For the quarter ending 2026-03-31, LUCD had -$6,829K decrease in cash & cash equivalents over the period.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Stock-based compensation - lucid diagnostics inc. 2018 equity plan | - | - | 1,135 | 2,092 |
| Debt extinguishment loss - senior secured convertible note | - | 0 | - | 0 |
| Net loss | -13,909 | -16,266 | -10,397 | -31,347 |
| Depreciation and amortization expense | 222 | 209 | 220 | 443 |
| Stock-based compensation-Lucid Diagnostics2018Equity Plan | 1,402 | 4,387 | - | - |
| Stock-based compensation - pavmed inc. 2014 equity plan | - | - | 17 | 82 |
| Stock-based compensation-Pavmed2014Equity Plan | 9 | 104 | - | - |
| Change in fair value - senior secured convertible note | -1,859 | -12,953 | -2,341 | 7,638 |
| Equity issuance cost extinguishment | - | - | 1,078 | - |
| Amortization of common stock payment for vendor service agreement | 29 | 0 | 87 | 147 |
| Equity issuance cost extinguishment | - | -1,078 | - | - |
| Accounts receivable | 46 | 96 | 177 | 328 |
| Prepaid expenses and other current assets | 1,247 | 616 | 283 | 942 |
| Due to pavmed inc. - operating expenses, employee related costs, msa fee | - | - | -4 | 16 |
| Accounts payable | 108 | 220 | -82 | -408 |
| Accrued expenses and other current liabilities | -519 | 443 | -146 | -407 |
| Due to pavmed inc. - operating expenses, employee related costs, msa fee-Pavmed | -9 | 16 | - | - |
| Net cash flows used in operating activities | -12,101 | -12,578 | -10,893 | -23,014 |
| Purchase of equipment | 215 | 51 | 28 | 118 |
| Purchase of intellectual property from pavmed inc | - | 0 | - | - |
| Net cash flows used in investing activities | -215 | -51 | -28 | -118 |
| Proceeds issue of common stock - registered direct offering, net of fees | - | - | 0 | 14,935 |
| Proceeds issue of common stock - confidentially marketed public offering, net of fees | - | - | 26,997 | 16,174 |
| Proceeds issue of preferred stock | - | 0 | - | 0 |
| Proceeds issue of common stock-Registered Direct Offering | 0 | 14,935 | - | - |
| Proceeds issue of common stock-Confidentially Marketed Public Offering | - | 43,171 | - | - |
| Proceeds issue of senior secured convertible notes | 0 | 0 | 0 | 360 |
| Payment repayment of senior secured convertible note | - | 0 | - | - |
| Proceeds issue of common stock-Atthemarket Offering | 5,274 | 274 | - | - |
| Proceeds issue of common stock at-the-market facility | - | - | 0 | 274 |
| Tax withholdings on equity based compensation | 17 | - | - | - |
| Proceeds exercise of stock options | 20 | 2 | 2 | 13 |
| Proceeds issue common stock employee stock purchase plan | 210 | 0 | 131 | 141 |
| Net cash flows provided by financing activities | 5,487 | 2 | 27,130 | 31,897 |
| Net (decrease) increase in cash | -6,829 | -12,627 | 16,209 | 8,765 |
| Cash, beginning of period | 34,705 | 47,332 | 22,358 | - |
| Cash, end of period | 27,876 | 34,705 | 47,332 | - |
Lucid Diagnostics Inc. (LUCD)
Lucid Diagnostics Inc. (LUCD)